Shares of Signal Genetics, Inc. (NASDAQ:SGNL) Up After Signing Merger with miRagen Therapeutics

Shares of Signal Genetics, Inc. (NASDAQ:SGNL) Up After Signing Merger with miRagen Therapeutics

Molecular diagnostics company, Signal Genetics, Inc. (NASDAQ:SGNL), announces signing of merger with privately-held biopharmaceutical company, Miragen Therapeutics, Inc. Signal Genetics, Inc. (SGNL) (“Signal”) and Miragen Therapeutics, Inc. (“miRagen”), a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of miRagen are currently estimated to become holders of approximately 96% of Signal’s outstanding common stock on a fully-diluted basis. The proposed merger […]

Read More ˃
pSivida, Corp. (NASDAQ:PSDV) Announces Release Date and Conference Call Information for First Quarter Fiscal Year 2017 Financial Results

pSivida, Corp. (NASDAQ:PSDV) Announces Release Date and Conference Call Information for First Quarter Fiscal Year 2017 Financial Results

Leader in the development of sustained release drug delivery products, pSivida, Corp. (NASDAQ:PSDV), announced that its financial results for Q1 will be released on Monday, November 7th. WATERTOWN, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the first quarter of fiscal year 2017 will be […]

Read More ˃
Neovasc, Inc. (NASDAQ:NVCN) Announces Litigation Update with CardiAQ, Stock Price Declines

Neovasc, Inc. (NASDAQ:NVCN) Announces Litigation Update with CardiAQ, Stock Price Declines

Specialty medical device company, Neovasc, Inc. (NASDAQ:NVCN), announces the findings of the Federal District Court regarding several post-trial motions following a May 2016 verdict. VANCOUVER, Nov. 1, 2016 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NVCN) (NVC.TO) reported today the findings of the Federal District Court regarding several post-trial motions stemming from a trial jury’s verdict in May 2016.  CardiAQ filed suit against Neovasc in the United States District […]

Read More ˃
Zion Oil & Gas, Inc. (NASDAQ:ZN) Reveals New, Simplified Stock Unit Option Program.  How Will the Market Respond?

Zion Oil & Gas, Inc. (NASDAQ:ZN) Reveals New, Simplified Stock Unit Option Program. How Will the Market Respond?

Oil and gas company, Zion Oil & Gas, Inc. (NASDAQ:ZN), announces a new Unit Option program under its Dividend Reinvestment and Common Stock Purchase Plan. DALLAS and CAESAREA, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) — Zion Oil & Gas, Inc. (NASDAQ:ZN) announces its new Unit Option program under its Dividend Reinvestment and Common Stock Purchase Plan (DSPP). “We are excited to launch this new Unit Option Program, which if successful, […]

Read More ˃
Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s Shares Tank After Reports of 3Q Loss

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s Shares Tank After Reports of 3Q Loss

Medical device company, Tandem Diabetes Care, Inc. (NASDAQ:TNDM), reports losses of $29.8 million in Q3, 2016. SAN DIEGO (AP) _ Tandem Diabetes Care Inc. (TNDM) on Tuesday reported a loss of $29.8 million in its third quarter. The San Diego-based company said it had a loss of 97 cents per share. The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research […]

Read More ˃
Lightbridge, Corp. (NASDAQ:LTBR) Reaches Agreement with AREVA on Terms for Joint Venture.  How Will the Market Respond?

Lightbridge, Corp. (NASDAQ:LTBR) Reaches Agreement with AREVA on Terms for Joint Venture. How Will the Market Respond?

Nuclear fuel development company, Lightbridge, Corp. (NASDAQ:LTBR), has agreed to terms with AREVA NP for a new joint venture. RESTON, Va., Nov. 02, 2016 (GLOBE NEWSWIRE) — Lightbridge Corporation (LTBR), a U.S. nuclear fuel development company, and AREVA NP, a leader in nuclear fuel, components and reactor services, have agreed upon key terms for the creation of a new joint venture to develop, manufacture and commercialize fuel assemblies based on […]

Read More ˃
Shares of CombiMatrix, Corp. (NASDAQ:CBMX) Up Following Results of Third Quarter 2016 Financial and Operating Report

Shares of CombiMatrix, Corp. (NASDAQ:CBMX) Up Following Results of Third Quarter 2016 Financial and Operating Report

Family health molecular diagnostics company, CombiMatrix, Corp. (NASDAQ:CBMX), reports financial results for Q3, 2016. Rapidly growing revenue, increasing test volume, gross margin expansion, strong cash reimbursement and prudent expense management provide clear path to profitability Conference call begins today at 4:30 p.m. Eastern time IRVINE, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) — CombiMatrix Corporation (CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, […]

Read More ˃
Shares of Medovex, Corp. (NASDAQ:MDVX) Advance Upon Announcement of Successful Largest Living Tissue Population Test to Date

Shares of Medovex, Corp. (NASDAQ:MDVX) Advance Upon Announcement of Successful Largest Living Tissue Population Test to Date

Developer of medical technology products, Medovex, Corp. (NASDAQ:MDVX), announced that it has conducted a successful live tissue test of their new DenerveX System. ATLANTA, GA–(Marketwired – Nov 2, 2016) – Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX™ System under the most stringent standards required by FDA and other regulatory agencies. Patrick Kullmann, Medovex […]

Read More ˃
O2Micro International, Ltd. (NASDAQ:OIIM) Experiences Revenue Growth Returns, Stock Price Advances

O2Micro International, Ltd. (NASDAQ:OIIM) Experiences Revenue Growth Returns, Stock Price Advances

Fabless semiconductor firm, O2Micro International, Ltd. (NASDAQ:OIIM), experiences revenue growth for the first time since Q4, 2013. O2Micro (OIIM) reported Q3 2016 revenues of $14.4 million versus $13.7 million a year ago, within the company’s guidance. More importantly, revenue grew year over year for the first time since Q4 2013 and guidance for Q4 is for revenues in the range of up 2-8% sequentially (or $14.7 to $15.6 million) versus […]

Read More ˃